We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+36.21%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.28B
AUM Growth
+$134M
Cap. Flow
-$102M
Cap. Flow %
-7.96%
Top 10 Hldgs %
51.02%
Holding
98
New
23
Increased
17
Reduced
22
Closed
15

Top Buys

1
ALR
Alere Inc
ALR
+$19.9M
2
NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
+$14.7M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$12M
4
ARCT icon
Arcturus Therapeutics
ARCT
+$9.78M
5
ACGN
Aceragen Inc
ACGN
+$9.6M

Top Sells

1
VOLC
VOLCANO CORPORATION COM STK
VOLC
+$44.6M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$34.2M
3
AMAG
AMAG Pharmaceuticals
AMAG
+$24.4M
4
ASRT
Assertio
ASRT
+$20.7M
5
KND
Kindred Healthcare
KND
+$20.2M

Sector Composition

1 Healthcare 91.84%
2 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$183M 14.27%
7,053,504
-1,864,471
-21% -$34.2M
AVDL
2
DELISTED
Avadel Pharmaceuticals
AVDL
$84.9M 6.61%
4,719,959
-433,231
-8% -$6.78M
TVTX icon
3
Travere Therapeutics
TVTX
$5.27B
$71M 5.53%
2,962,298
+303,444
+11% +$4.63M
AEGR
4
DELISTED
Aegerion Pharmaceuticals
AEGR
$65.5M 5.1%
2,502,578
-46,285
-2% -$1.18M
PGNX
5
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$53.5M 4.17%
8,951,169
– –
EBS icon
6
Emergent Biosolutions
EBS
$394M
$52.1M 4.06%
1,810,519
-256,200
-12% -$7.35M
ANGO icon
7
AngioDynamics
ANGO
$558M
$42.7M 3.32%
2,398,527
-272,176
-10% -$5.06M
HRTX icon
8
Heron Therapeutics
HRTX
$89.1M
$40.9M 3.18%
2,808,173
– –
AMPH icon
9
Amphastar Pharmaceuticals
AMPH
$871M
$31.8M 2.48%
2,127,854
– –
RIGL icon
10
Rigel Pharmaceuticals
RIGL
$750M
$29.4M 2.29%
824,633
-25,542
-3% -$700K
BDSI
11
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$23.6M 1.84%
2,246,399
-150,000
-6% -$2.05M
PTX
12
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$23.2M 1.81%
216,833
-88,167
-29% -$8.4M
ALR
13
DELISTED
Alere Inc
ALR
$22.1M 1.72%
+452,423
New +$19.9M
ACGN
14
DELISTED
Aceragen Inc
ACGN
$21M 1.64%
41,688
+15,738
+61% +$9.6M
PETX
15
DELISTED
Aratana Therapeutics, Inc.
PETX
$18.1M 1.41%
1,131,865
-127,606
-10% -$2.27M
DSCI
16
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$18M 1.41%
2,130,477
+273,600
+15% +$2.33M
CPRX icon
17
Catalyst Pharmaceutical
CPRX
$17.7M 1.38%
4,083,177
+1,683,177
+70% +$6.07M
RXDX
18
DELISTED
Ignyta, Inc.
RXDX
$17.3M 1.35%
1,741,700
+1,100,000
+171% +$8.23M
DVAX
19
DELISTED
Dynavax Technologies
DVAX
$17.2M 1.34%
766,010
– –
ASRT
20
DELISTED
Assertio
ASRT
$15.8M 1.23%
11,753
-16,809
-59% -$20.7M
ZGNX
21
DELISTED
Zogenix, Inc.
ZGNX
$14.7M 1.15%
1,342,206
+562,500
+72% +$6.36M
HZNP
22
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$13M 1.01%
500,000
+200,000
+67% +$3.67M
LJPC
23
DELISTED
La Jolla Pharmaceutical Company
LJPC
$12.9M 1%
703,470
-417,900
-37% -$8.47M
IOVA icon
24
Iovance Biotherapeutics
IOVA
$2.23B
$12.9M 1%
+1,062,419
New +$12M
SCTL
25
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$12.8M 1%
1,576,089
– –
1
2 3 4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2015 Portfolio in Review

As of Q1 2015, Broadfin Capital held 98 positions worth $1.28B, up 12% from $1.15B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Broadfin Capital withdrew a net $102M in Q1 2015, closing 15 positions and reducing 22 holdings. Its most notable exit was VOLCANO CORPORATION COM STK, an estimated $44.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 83% a quarter earlier, followed by Consumer Discretionary.

Against the trend, Broadfin Capital opened a new position in Alere Inc worth $22.1M.

  • Broadfin Capital's largest Q1 2015 buy was Alere Inc: 452,423 shares worth $22.1M.
  • Broadfin Capital added most to Aceragen Inc in Q1 2015, an estimated $9.6M increase.
  • Broadfin Capital's biggest Q1 2015 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $34.2M.
  • Broadfin Capital fully exited VOLCANO CORPORATION COM STK in Q1 2015, selling an estimated $44.6M.
  • Broadfin Capital's ten largest holdings make up 51% of its $1.28B portfolio in Q1 2015.
  • Broadfin Capital opened 23 new positions and closed 15 in Q1 2015.
  • Broadfin Capital's portfolio value rose 12% quarter-over-quarter to $1.28B.

Based on Broadfin Capital's 13F filing for Q1 2015, filed 15 May 2015.